Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term secukinumab withdrawal extension in moderate to severe hidradenitis suppurativa
2019-003230-17Phase 3Unknown
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Secukinumab continuation arm with Placebo withdrawal arm (2 arms). Primary endpoint: Time to loss of response up to Week 104. Status: unknown.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2019-003230-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003230-17.